SCM
MPLT

Sterling Capital Management’s MapLight Therapeutics MPLT Stock Holding History

Sterling Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01K Sell
56
-314
-85% -$9.03K ﹤0.01% 2992
2026
Q1 		$7.52K Sell
370
-149
-29% -$2.67K ﹤0.01% 2523
2025
Q4 		$9.12K Buy
+519
New +$8.7K ﹤0.01% 2656

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's MPLT Position: Q2 2026 in Review

Sterling Capital Management reduced its MapLight Therapeutics (MPLT) stake by 85% in Q2 2026, selling an estimated $9.03K and leaving 56 shares worth $2.01K. The position accounts for ﹤0.01% of the portfolio, ranked #2992.

Sterling Capital Management first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.12K in Q4 2025. 106 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Sterling Capital Management held 56 shares of MapLight Therapeutics worth $2.01K as of Q2 2026.
  • Sterling Capital Management sold 314 MapLight Therapeutics shares in Q2 2026, an estimated $9.03K.
  • MapLight Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2992 holding.
  • Sterling Capital Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Sterling Capital Management's MapLight Therapeutics position peaked at $9.12K in Q4 2025.
  • 106 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.